

Robert A Mccutcheon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7708781/publications.pdf>

Version: 2024-02-01

71
papers

5,767
citations

201674

27
h-index

102487

66
g-index

82
all docs

82
docs citations

82
times ranked

6470
citing authors

#	ARTICLE	IF	CITATIONS
1	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. <i>Molecular Psychiatry</i> , 2023, 28, 1995-2006.	7.9	13
2	Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3150-3156.	4.5	4
3	Reinventing schizophrenia: The rules of the game. <i>Schizophrenia Research</i> , 2022, 242, 94-95.	2.0	3
4	Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 135, 104568.	6.1	8
5	Assessing the impact of different penalty factors of the Bayesian reconstruction algorithm Q.Clear on in vivo low count kinetic analysis of [11C]PHNO brain PET-MR studies. <i>EJNMMI Research</i> , 2022, 12, 11.	2.5	7
6	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. <i>British Journal of Psychiatry</i> , 2022, 221, 740-747.	2.8	6
7	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis. <i>World Psychiatry</i> , 2022, 21, 287-294.	10.4	26
8	The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study. <i>Molecular Psychiatry</i> , 2022, 27, 3493-3500.	7.9	2
9	Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. <i>Translational Psychiatry</i> , 2022, 12, 198.	4.8	7
10	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. <i>Molecular Psychiatry</i> , 2021, 26, 1310-1320.	7.9	47
11	Magnitude and variability of structural brain abnormalities in neuropsychiatric disease: protocol for a network meta-analysis of MRI studies. <i>Evidence-Based Mental Health</i> , 2021, 24, 111-114.	4.5	2
12	Individual Differences in Response to Antidepressants. <i>JAMA Psychiatry</i> , 2021, 78, 490.	11.0	26
13	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2021, 11, 322.	4.8	10
14	Acute psychological impact of coronavirus disease 2019 outbreak among psychiatric professionals in China: a multicentre, cross-sectional, web-based study. <i>BMJ Open</i> , 2021, 11, e047828.	1.9	2
15	Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. <i>Science Advances</i> , 2021, 7, .	10.3	13
16	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 425.	4.8	14
17	Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls. <i>World Psychiatry</i> , 2021, 20, 405-416.	10.4	22
18	Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. <i>Neuropsychopharmacology</i> , 2020, 45, 641-648.	5.4	21

#	ARTICLE	IF	CITATIONS
19	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. <i>Neuropharmacology</i> , 2020, 172, 107704.	4.1	180
20	Schizophrenia—An Overview. <i>JAMA Psychiatry</i> , 2020, 77, 201.	11.0	569
21	Treatment of First-Episode Schizophrenia in a Young Woman. <i>JAMA Psychiatry</i> , 2020, 77, 211.	11.0	1
22	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. <i>Molecular Psychiatry</i> , 2020, 25, 1704-1717.	7.9	39
23	Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. <i>World Psychiatry</i> , 2020, 19, 15-33.	10.4	301
24	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 64-77.	7.4	506
25	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. <i>Neuropsychopharmacology</i> , 2020, 45, 622-631.	5.4	63
26	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. <i>Journal of Affective Disorders</i> , 2020, 276, 991-1000.	4.1	11
27	Cannabis Use Linked to Altered Functional Connectivity of the Visual Attentional Connectivity in Patients With Psychosis and Controls. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	7
28	Disentangling relapse and adherence in psychosis. <i>Lancet Psychiatry</i> , 2020, 7, 722-723.	7.4	4
29	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq1 1 0.784314 rgBT /Ove		
30	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e204693.	5.9	103
31	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 344-353.	7.4	147
32	Sleep and Circadian Rhythm Disturbance in Remitted Schizophrenia and Bipolar Disorder: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1126-1143.	4.3	83
33	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 1040-1051.	1.5	11
34	Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. <i>Molecular Psychiatry</i> , 2019, 24, 776-794.	7.9	124
35	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. <i>Scientific Reports</i> , 2019, 9, 8685.	3.3	17
36	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. <i>Journal of Psychopharmacology</i> , 2019, 33, 1248-1253.	4.0	24

#	ARTICLE	IF	CITATIONS
37	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. <i>European Neuropsychopharmacology</i> , 2019, 29, 1333-1342.	0.7	8
38	The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [¹¹ C]-(+)-PHNO PET study. <i>Translational Psychiatry</i> , 2019, 9, 287.	4.8	23
39	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. <i>Psychopharmacology</i> , 2019, 236, 3257-3270.	3.1	21
40	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. <i>Psychopharmacology</i> , 2019, 236, 1985-1997.	3.1	35
41	Mesolimbic dopamine function and salience network connectivity: An integrative PET and MR study. <i>European Neuropsychopharmacology</i> , 2019, 29, S596-S597.	0.7	0
42	The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, S611.	0.7	1
43	Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity. <i>Schizophrenia Research</i> , 2019, 213, 56-64.	2.0	25
44	A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. <i>Schizophrenia Bulletin</i> , 2019, 45, 1120-1133.	4.3	113
45	Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. <i>Trends in Neurosciences</i> , 2019, 42, 205-220.	8.6	441
46	Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study. <i>Biological Psychiatry</i> , 2019, 85, 368-378.	1.3	72
47	Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory. <i>ELife</i> , 2019, 8, .	6.0	17
48	The effects of psychosocial stress on dopaminergic function and the acute stress response. <i>ELife</i> , 2019, 8, .	6.0	53
49	The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis. <i>Neuropsychopharmacology</i> , 2018, 43, 1195-1196.	5.4	4
50	Amygdala reactivity in ethnic minorities and its relationship to the social environment: an fMRI study. <i>Psychological Medicine</i> , 2018, 48, 1985-1992.	4.5	12
51	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1301-1311.	4.3	187
52	Antipsychotic plasma levels in the assessment of poor treatment response in Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 39-46.	4.5	76
53	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. <i>Lancet Psychiatry</i> , 2018, 5, 816-823.	7.4	89
54	F226. The Relationship Between Cortical Glutamate and Striatal Dopamine Function in Psychosis: A Multi-Modal PET and MRS Imaging Study in First Episode Psychosis. <i>Biological Psychiatry</i> , 2018, 83, S326-S327.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. <i>Translational Psychiatry</i> , 2017, 7, e1024-e1024.	4.8	193
56	Ethnicity, the amygdala, and the social environment: a neuroimaging study. <i>Lancet, The</i> , 2017, 389, S67.	13.7	0
57	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
58	282. Amygdala Reactivity in Ethnic Minority Individuals, and Its Relationship to the Social Environment. <i>Biological Psychiatry</i> , 2017, 81, S116.	1.3	0
59	The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, 9-20.	1.3	416
60	Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. <i>Lancet Psychiatry,the</i> , 2016, 3, 451-463.	7.4	106
61	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. <i>Biological Psychiatry</i> , 2016, 80, e19-e20.	1.3	4
62	Methodology of the SEYLE trial on suicide prevention in schools. <i>Lancet, The</i> , 2015, 386, 853-854.	13.7	0
63	̢ ₂ -Adrenoceptor blockade modulates fusiform gyrus activity to black versus white faces. <i>Psychopharmacology</i> , 2015, 232, 2951-2958.	3.1	10
64	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. <i>Journal of Psychopharmacology</i> , 2015, 29, 892-897.	4.0	51
65	Glutamate and dopamine in schizophrenia: An update for the 21 st century. <i>Journal of Psychopharmacology</i> , 2015, 29, 97-115.	4.0	596
66	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 427-438.	4.5	38
67	The diagnosis debate. <i>Lancet Psychiatry,the</i> , 2014, 1, 498.	7.4	0
68	Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. <i>Psychopharmacology</i> , 2014, 231, 4323-4335.	3.1	44
69	Community treatment orders for patients with psychosis. <i>Lancet, The</i> , 2013, 382, 501.	13.7	5
70	Letter to the Editor. <i>Journal of Anxiety Disorders</i> , 2013, 27, 543.	3.2	1
71	Commissions, coercion and choice. <i>The Psychiatrist</i> , 2013, 37, 179-179.	0.3	0